AssemblyBio_logo_RGB.png
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05. März 2021 17:00 ET | Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., March 05, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
AssemblyBio_logo_RGB.png
Assembly Biosciences Reports Fourth Quarter and Year End 2020 Financial Results and Recent Highlights
25. Februar 2021 16:05 ET | Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
AssemblyBio_logo_RGB.png
Assembly Biosciences Updates Pipeline Strategy, Focusing on Finite and Curative Therapies for Chronic Hepatitis B Virus Infection
25. Februar 2021 16:00 ET | Assembly Biosciences, Inc.
- Prioritizing next generation, more potent core inhibitors, triple combinations with complementary mechanisms of action, and expanding research programs to advance multiple candidates against novel...
AssemblyBio_logo_RGB.png
Assembly Bio Announces Upcoming Investor Events
19. Februar 2021 08:00 ET | Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
AssemblyBio_logo_RGB.png
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05. Februar 2021 17:00 ET | Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
AssemblyBio_logo_RGB.png
Assembly Biosciences to Wind-Down Microbiome Program
08. Dezember 2020 16:02 ET | Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
AssemblyBio_logo_RGB.png
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04. Dezember 2020 16:30 ET | Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
AssemblyBio_logo_RGB.png
Assembly Biosciences Appoints Nicole S. White, PhD, as Senior Vice President of Pharmaceutical Development and Manufacturing
17. November 2020 08:00 ET | Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...
AssemblyBio_logo_RGB.png
Assembly Biosciences and Door Pharmaceuticals Sign Collaboration and Option Agreement to Develop a Novel Class of HBV Core Protein Modulators
16. November 2020 08:00 ET | Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) and Door Pharmaceuticals, LLC today announced that the companies have signed an exclusive,...
AssemblyBio_logo_RGB.png
Assembly Biosciences Presents Data from HBV Core Inhibitor Programs in Poster Sessions at the 2020 AASLD The Liver Meeting Digital Experience™
13. November 2020 08:00 ET | Assembly Biosciences, Inc.
- Data show longer-term, differentiated safety profile of vebicorvir and the importance of HBV pregenomic (pg) RNA as a key biomarker, as well as highlight Assembly Bio’s core inhibitor clinical...